Alerts will be sent to your verified email
Verify EmailINDOCO
|
Indoco Remedies
|
Panacea Biotec
|
Kwality Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
54.0 . | 6.0 . | n/a |
|
Number of ANDA's Approved By USFDA
|
32.0 . | n/a | n/a |
|
Domestic Sales Growth - YoY
|
4.0 % | n/a | n/a |
|
US DMF Filings
|
26.0 . | n/a | n/a |
|
Global DMFs filed
|
147.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
5.7 % | 9.86 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
8.94 % | 36.5 % | 25.27 % |
|
5yr average Equity Multiplier
|
1.9 | 0.36 | 1.96 |
|
5yr Average Asset Turnover Ratio
|
0.88 | 0.41 | 1.05 |
|
5yr Avg Net Profit Margin
|
5.41 % | 26.1 % | 11.66 % |
|
Price to Book
|
1.89 | 2.43 | 5.42 |
|
P/E
|
0.0 | 0.0 | 27.79 |
|
5yr Avg Cash Conversion Cycle
|
35.3 Days | -170.26 Days | 55.02 Days |
|
Inventory Days
|
70.6 Days | 120.03 Days | 67.04 Days |
|
Days Receivable
|
83.16 Days | 42.2 Days | 132.46 Days |
|
Days Payable
|
111.01 Days | 325.14 Days | 126.93 Days |
|
5yr Average Interest Coverage Ratio
|
7.53 | 2.7 | 16.13 |
|
5yr Avg ROCE
|
13.6 % | -2.79 % | 34.73 % |
|
5yr Avg Operating Profit Margin
|
14.97 % | -3.85 % | 23.23 % |
|
5 yr average Debt to Equity
|
0.49 | -0.69 | 0.46 |
|
5yr CAGR Net Profit
|
n/a | -43.68 % | 21.34 % |
|
5yr Average Return on Assets
|
5.31 % | 9.32 % | 12.96 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
58.9 % | 72.48 % | 54.83 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.21 % | -1.11 % | 0.38 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.27 % | 0.0 | 0.0 |
|
Indoco Remedies
|
Panacea Biotec
|
Kwality Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|